No Data
No Data
Southwest Securities released a research report on April 26 stating that it gave Weining Health (300253.SZ) a purchase rating, and the target price was 9.20 yuan. The main reasons for the rating include: 1) steady growth in healthcare informatization reve
Southwest Securities released a research report on April 26 stating that it gave Weining Health (300253.SZ) a purchase rating, and the target price was 9.20 yuan. The main reasons for the rating include: 1) steady growth in healthcare informatization revenue; 2) promotion of “1+X” strategy upgrade and continued implementation of the WineX benchmark; 3) forward-looking AI+ medical informatization, and the recovery of the downstream economy is worth looking forward to. (Mainichi Keizai Shimbun)
Weining Health (300253.SZ): Net profit of 166.204 million yuan for the first quarter reversed year-on-year losses
On April 26, Ge Longhui Health (300253.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 494 million yuan, up 10.09% year on year; net profit attributable to shareholders of listed companies was 166.204 million yuan, turning a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 8.6877 million yuan; basic earnings per share were 0.0077 yuan.
Weining Health (300253): Profit recovery clearly accelerates implementation of “1+X”
Incident: The company released its 2023 annual report, achieving operating income of 3.16 billion yuan, an increase of 2.3% over the previous year; realized net profit of 360 million yuan, an increase of 229.5% over the previous year; and realized net profit without deduction of 330 million yuan.
China Galaxy released a research report on April 22 stating that it maintains the Weining Health (300253.SZ) recommendation rating. The main reasons for the rating include: 1) the medical and health information technology business is growing steadily, and
China Galaxy released a research report on April 22 stating that it maintains the Weining Health (300253.SZ) recommendation rating. The main reasons for the rating include: 1) the medical and health information technology business is growing steadily, and losses in the innovative business sector have narrowed; 2) gross margin has increased, and the cost control effect has reached a new high level of profit per capita; 3) the “1+X” strategy continues to be upgraded, and WineX products help the hospital's digital transformation and high-quality development. (Mainichi Keizai Shimbun)
Weining Health (300253): Healthcare IT revenue rises steadily, innovative business losses narrow
Investment highlights: Incident: Weining Health released its 2023 financial report, achieving operating income of 3.163 billion yuan, an increase of 2.28% over the previous year, and net profit to mother of 358 million yuan, an increase of 229.49% over the previous year, after deducting net income from the mother
Winning Health Technology Group Co., Ltd. Just Missed Revenue By 5.6%: Here's What Analysts Think Will Happen Next
It's shaping up to be a tough period for Winning Health Technology Group Co., Ltd. (SZSE:300253), which a week ago released some disappointing full-year results that could have a notable impact on how
No Data